Last updated on July 2019

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT


Brief description of study

The investigators wish to evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with Idiopathic Pulmonary Fibrosis.

Detailed Study Description

Stanford University has developed a new PET tracer that selectively binds to integrin avb6, a cell surface receptor that is overexpressed in idiopathic pulmonary fibrosis (IPF). Increased avb6 receptors on IPF lung tissue has been well documented, while its expression remains relatively non-existent in the healthy adult lung.

The selected PET tracer [18F]FP-R01-MG-F2 has shown promise identifying integrin avb6 in both preclinical and clinical studies at Stanford University. The investigators have demonstrated low [18F]FP-R01-MG-F2 radiopharmaceutical uptake in the heart and lung region of healthy volunteers, which was an expected biodistribution (the normal tissue uptake of the radiopharmaceutical within the body) based on immunohistochemical staining of healthy lung tissue, which demonstrated the presence of minimal avb6 receptors in healthy lung tissue.

OBJECTIVE

To evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with IPF. Feasibility will be measured by drawing regions of interest (ROI) around the lungs of participants with IPF and the lungs of healthy adult volunteers and comparing the calculated standarized uptake value maximum(s) (SUVmax).

The tracer's physiologic biodistribution, safety and tolerability will also be studied.

Clinical Study Identifier: NCT03183570

Find a site near you

Start Over

Stanford University

Stanford, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.